Research programme: CNS therapies - Xenon

Drug Profile

Research programme: CNS therapies - Xenon

Alternative Names: CNS 1; CNS therapies research programme - Xenon; Neurological therapies research programme - Xenon; Research programme: neurological therapies - Xenon

Latest Information Update: 01 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 20 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)
  • 29 Jun 2004 Xenon Genetics is now called Xenon Pharmaceuticals
  • 14 Nov 2002 Early research in CNS disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top